908 Devices, a pioneer of purpose-built handheld and desktop Mass Spec devices for chemical and biomolecular analysis, today announced the appointment of Kevin Hrusovsky as the Chairman of its Board of Directors. Mr. Hrusovsky, who has served on the 908 Devices Board of Directors since 2013, is a biotech entrepreneur and healthcare visionary with a passion for revolutionizing healthcare and a proven track record of commercializing disruptive technologies.
“Our devices are used by our customers who need answers quickly, at the point-of-need to interrogate the unknown-and-invisible and provide actionable answers to address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, and forensics.” said Dr. Kevin J. Knopp, CEO and Co-Founder of 908 Devices. “Kevin Hrusovsky’s deep knowledge and experience are incredibly additive as we democratize laboratory Mass Spectrometry instruments with our simple handheld and desktop devices.”
“There has never been a more important time in science to harness advanced analytical tools,” said Mr. Hrusovsky. “I’m honored to be named Chairman and committed to supporting technologies that accelerate outcomes and disrupt healthcare. Kevin Knopp and the 908 Devices team are democratizing Mass Spectrometry at an important inflection point for next generation Proteomics and its promise to revolutionize healthcare.”
Kevin Hrusovsky currently serves as the Chairman, CEO and President of Quanterix (NASDAQ: QTRX), a company digitizing biomarker analysis to advance precision health. He is also the founder of Powering Precision Health (PPH) foundation, a non-profit global think tank composed of the industry’s top medical, research and financial experts. Through his non-profit network and the power of Quanterix’s disruptive Simoa technology, Mr. Hrusovsky is accelerating critical advances across neurology, oncology, infectious disease, cardiology, and inflammation.
A dynamic and respected thought leader, Hrusovsky is regularly sought after by mainstream media, including CBS, NBC, CNN, and other major news outlets to speak on the promise of precision health to diagnose diseases before symptoms even occur. Most recently, Mr. Hrusovsky spearheaded a newly formed Emergency COVID-19 Diagnostic & Drug PPH Advisory Panel that aims to enhance global understanding of COVID-19, including the innate and adaptive immune response to drive earlier intervention in the disease cascade, deliver more targeted therapeutic responses, and accelerate development of emerging drugs and vaccines.